SPHL:NASDAQSpringview Holdings Ltd Analysis
Data as of 2026-06-06 - not real-time
$5.35
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Springview Holdings is trading at $5.35, well above its 20‑day SMA of $2.74 and 50‑day SMA of $2.63, yet still far below the 200‑day SMA of $3.54, indicating a short‑term price surge that lacks long‑term support. The technical picture is mixed: a bullish MACD histogram (+0.17) and a very high RSI of 83 suggest strong upward momentum but also signal that the stock is in overbought territory. Volatility is extreme, with a 30‑day swing of roughly 248% and a historic max drawdown of –87%, underscoring the risk of rapid price reversals. Fundamentals are weak – the company posts negative operating (‑48%) and profit margins (‑30%), negative cash flows, and a price‑to‑book of 13.9, implying the market is pricing in significant growth expectations despite poor earnings.
Recent news adds a layer of uncertainty: the firm secured a major heritage redevelopment contract in Singapore, which could provide a catalyst for revenue, but it also received a Nasdaq notice concerning minimum bid requirements, raising potential compliance concerns. Investors should weigh the short‑term technical upside against the deep‑seated financial weaknesses and heightened volatility before deciding on exposure.
Recent news adds a layer of uncertainty: the firm secured a major heritage redevelopment contract in Singapore, which could provide a catalyst for revenue, but it also received a Nasdaq notice concerning minimum bid requirements, raising potential compliance concerns. Investors should weigh the short‑term technical upside against the deep‑seated financial weaknesses and heightened volatility before deciding on exposure.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- RSI in overbought territory
- Extreme 30‑day volatility
- Negative earnings and cash flow
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Potential revenue uplift from new heritage contract
- Continued earnings pressure
- High price‑to‑book ratio
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Fundamental turnaround required
- Sector cyclicality may eventually support demand
- Regulatory and compliance uncertainties
Key Metrics & Analysis
Financial Health
Revenue Growth5.80%
Profit Margin-30.13%
ROE-35.42%
ROA-13.99%
Debt/Equity15.28
P/B Ratio13.9
Op. Cash Flow$-2039992
Free Cash Flow$-2355800
Technical Analysis
TrendNeutral
RSI83.3
Support$2.30
Resistance$10.71
MA 20$2.74
MA 50$2.63
MA 200$3.54
MACDBullish
VolumeIncreasing
Fear & Greed Index83.02
Valuation
GradeOvervalued
TypeValue
Risk Assessment
Beta-0.23
Volatility248.28%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.